Clinical Trials Browser

Approved for marketing × Lymphoma, Mantle-Cell × ibrutinib × Clear all

NCT01833039 2025-02-03

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Approved for marketing

Recurrence, Lymphoma, Mantle-Cell